Effect of Theta Burst Stimulation on Alcohol Cue Reactivity

NCT ID: NCT04223154

Last Updated: 2023-05-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-26

Study Completion Date

2021-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alcohol Use Disorder (AUD) is prevalent, devastating, and difficult to treat. The intransigence of AUD is readily apparent in the Trauma Unit of Wake Forest University Baptist Hospital, wherein 23% of trauma related admissions are associated with alcohol - higher than the national average of 16%. Of these trauma related admissions, over 70% are estimated to have AUD and 41% will be likely be admitted to the trauma unit again within 5 years. While Dr. Veach (Co-Investigator) and her team in the Department of Surgery have demonstrated that a brief counseling intervention on the inpatient trauma unit can decrease morbidity and recidivism, the rates of AUD and relapse to drinking among these individuals remains very high. With a growing knowledge of the neural circuits that contribute to relapse in AUD, there is an emerging interest in developing a novel, neural-circuit specific therapeutic tool to enhance AUD treatment outcomes.

This will be achieved through a double-blind, sham-controlled cohort study in heavy alcohol drinkers with a history of alcohol-related injury. The brain reactivity to alcohol cues (Incentive Salience) and cognitive performance in the presence of an alcoholic beverage cue (Cognitive Control) will be measured immediately before and after participants receive real or sham intermittent theta burst stimulation (iTBS- a potentiating form of transcranial magnetic stimulation (TMS)) to the dorsolateral prefrontal cortex (dlPFC iTBS). The goals of this pilot study are to quantify the acute effect of a single session of real or sham dlPFC iTBS on brain response to alcohol cues (Aim 1) and cognitive flexibility in the presence of an alcohol cue (Aim 2) among risky drinkers (target engagement ).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alcohol Use Disorder (AUD) is prevalent, devastating, and difficult to treat. The intransigence of AUD is readily apparent in the Trauma Unit of Wake Forest University Baptist Hospital, wherein 23% of trauma related admissions are associated with alcohol - higher than the national average of 16%. Of these trauma related admissions, over 70% are estimated to have AUD and 41% will be likely be admitted to the trauma unit again within 5 years. While Dr. Veach (Co-Investigator) and her team in the Department of Surgery have demonstrated that a brief counseling intervention on the inpatient trauma unit can decrease morbidity and recidivism, the rates of AUD and relapse to drinking among these individuals remains very high. With a growing knowledge of the neural circuits that contribute to relapse in AUD, there is an emerging interest in developing a novel, neural-circuit specific therapeutic tool to enhance AUD treatment outcomes. The long term goal of the multidisciplinary research team (Hanlon \& Veach) is to develop an evidence-based brain stimulation treatment which can ultimately be prescribed to individuals that present to the Trauma Unit with AUD - decreasing their drinking and hospital recidivism.

The competing neurobehavioral decision systems (CNDS) theory posits that in addiction, choice results from a regulatory imbalance between two decision-making systems (impulsive and executive). These behavioral systems are functionally linked to two functional connectivity networks which regulate the incentive salience of the alcohol cue (Salience Network) and cognitive flexibility required for a vulnerable individual to shift attention away from the alcohol cue (Central Executive Network). Modulating these competing neural circuits (e.g. either dampening the incentive salience associated with alcohol cues (Strategy 1) or amplifying cognitive control in the presence of a cue (Strategy 2) may render alcohol users less vulnerable to relapse. Over the past 7 years, Dr. Hanlon's human brain stimulation research group has been focused on focused on Strategy 1 - dampening alcohol craving and brain reactivity to alcohol cues among heavy alcohol drinkers at risk for AUD or relapse to alcohol use. These studies led to a formal double-blind sham-controlled clinical trial of medial prefrontal cortex (mPFC) continuous theta burst stimulation (cTBS) in treatment-seeking alcohol users. Unfortunately, however, this approach is associated with more pain at the stimulation site (forehead) which undermines its promise as a tool to be readily scaled to a larger population, and it is not clear that this improves the attentional bias towards alcohol cues among these individuals.

Hence, the goal of this proposal is to evaluate Strategy 2 of the CNDS theory- increasing activity in executive control circuitry- as an innovative approach to dampening alcohol cue-reactivity (Aim 1) and improving cognitive control in the presence of an alcohol cue (Aim 2). This will be achieved through a double-blind, sham-controlled cohort study in heavy alcohol drinkers with a history of alcohol-related injury. The brain reactivity to alcohol cues (Incentive Salience) and cognitive performance in the presence of an alcoholic beverage cue (Cognitive Control) will be measured immediately before and after participants receive real or sham intermittent theta burst stimulation (iTBS- a potentiating form of transcranial magnetic stimulation (TMS)) to the dorsolateral prefrontal cortex (dlPFC iTBS). iTBS is a high-potency form of brain stimulation wherein two minutes of iTBS (600 pulses) leads to an increase in cortical excitability that lasts for approximately 30 minutes. In 2018 dlPFC iTBS was FDA-cleared as a treatment for major depressive disorder (wherein 30 sessions over 6 weeks lead to a sustained decrease in depressive symptoms for 6 months). In 2019, the first 2 manuscripts were published demonstrating that iTBS decreases cue-reactivity to cocaine. The goals of this pilot study are to quantify the acute effect of a single session of real or sham dlPFC iTBS on brain response to alcohol cues (Aim 1) and cognitive flexibility in the presence of an alcohol cue (Aim 2) among risky drinkers ("target engagement").

Aim 1: Evaluate the effect of dlPFC iTBS on alcohol cue-reactivity. The blood-oxygen level dependent (BOLD) signal associated with exposure to alcohol cues will be measured before and after sham and real iTBS using a validated, patient-tailored alcohol/non-alcoholic beverage cue task. Hypothesis: cue-evoked functional connectivity in the mPFC, anterior cingulate cortex (ACC), amygdala, and ventral striatum will be attenuated after real but not sham iTBS.

Aim 2: Evaluate the effect of dlPFC iTBS on cognitive performance in the presence of an alcohol cue. Following the alcohol cue reactivity task all individuals will perform the well-known alcohol Stroop task (downloaded from the NIH toolbox) on a Tablet PC while a glass of the participant's preferred alcoholic beverage (beer, wine, liquor) is placed within 5 feet of the participant (but out of arms length). This will occur before and after TBS. The participant will not be allowed to consume the drink. Hypothesis: Stroop accuracy and reaction time will be impaired at baseline, but this difference will be attenuated by real (but not sham) iTBS to the dlPFC (three way mixed model ANOVA, correcting for multiple comparisons).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Drinking Alcohol Use Disorder Trauma Injury Alcohol Dependence Alcohol Abuse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Real TBS to the dlPFC

One session of real intermittent Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)

Group Type EXPERIMENTAL

Real iTBS to the dlPFC

Intervention Type DEVICE

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

Sham TBS to the dlPFC

One session of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)

Group Type SHAM_COMPARATOR

Sham iTBS to the dlPFC

Intervention Type DEVICE

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Real iTBS to the dlPFC

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

Intervention Type DEVICE

Sham iTBS to the dlPFC

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ages 21-65.
2. Alcohol use disorder identification test score \>7
3. Drink at least 20 standard sized alcohol beverage servings per week

Exclusion Criteria

1. Current use of prescription or illicit psychoactive drugs (except marijuana or nicotine) known to decrease seizure threshold by self-report in the last 30 days.
2. Currently meets DSM-V criteria for substance use disorder for a substance other than alcohol, marijuana, or nicotine.
3. Has current suicidal or homicidal ideation.
4. Current breath alcohol concentration \>0.002
5. Not currently at risk for withdrawal, as indicated by CIWA-Ar \>5.
6. History of seizures or seizure disorder(s).
7. Females of childbearing potential who are pregnant (by urine HCG), planning to become pregnant, nursing, or who are not using a reliable form of birth control.
8. Any other violation of MRI/TMS safety measures.
9. Unable to read and understand questionnaires, assessments, and the informed consent.
10. No presence of metal objects in the head/neck.
11. History of traumatic brain injury resulting in hospitalization, loss of consciousness for more than 10 minutes, and/or having ever been informed he/she has an epidural, subdural, or subarachnoid hemorrhage.
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wake Forest University Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Colleen Hanlon, PhD

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wake Forest Baptist Health Sciences

Winston-Salem, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB00063018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The iHealth Study in College Students
NCT00183131 COMPLETED PHASE2
Measuring the Neuroimmune Response to Alcohol
NCT04251221 COMPLETED EARLY_PHASE1
Mobile Alcohol Use Intervention
NCT07126613 COMPLETED NA
Decisions During Drinking
NCT06978140 COMPLETED NA